Precipio, Inc. (NASDAQ:PRPO) Sees Large Decline in Short Interest

Precipio, Inc. (NASDAQ:PRPO) was the recipient of a large decrease in short interest in December. As of December 15th, there was short interest totaling 4,124 shares, a decrease of 44.2% from the November 30th total of 7,388 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average daily volume of 9,360 shares, the short-interest ratio is currently 0.4 days. Based on an average daily volume of 9,360 shares, the short-interest ratio is currently 0.4 days. Approximately 0.3% of the shares of the company are sold short.

Institutional Trading of Precipio

Hedge funds have recently bought and sold shares of the stock. Susquehanna International Group LLP purchased a new position in shares of Precipio during the third quarter valued at about $194,000. Topline Capital Management LLC bought a new position in Precipio during the third quarter valued at approximately $1,158,000. Evernest Financial Advisors LLC purchased a new position in Precipio during the 3rd quarter valued at approximately $374,000. Finally, AMH Equity Ltd increased its stake in Precipio by 370.1% in the 3rd quarter. AMH Equity Ltd now owns 131,100 shares of the biotechnology company’s stock worth $2,332,000 after acquiring an additional 103,210 shares during the last quarter. Hedge funds and other institutional investors own 10.45% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on PRPO shares. Wall Street Zen downgraded Precipio from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Precipio in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Precipio Price Performance

Shares of NASDAQ PRPO traded down $0.39 during mid-day trading on Friday, reaching $23.50. The company’s stock had a trading volume of 5,600 shares, compared to its average volume of 8,557. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.27 and a quick ratio of 1.10. Precipio has a 52 week low of $3.90 and a 52 week high of $28.50. The stock has a fifty day moving average of $22.53 and a two-hundred day moving average of $17.88. The firm has a market capitalization of $41.13 million, a PE ratio of -28.66 and a beta of 1.09.

Precipio (NASDAQ:PRPO) last posted its quarterly earnings results on Friday, November 14th. The biotechnology company reported ($0.05) EPS for the quarter. Precipio had a negative return on equity of 10.07% and a negative net margin of 5.50%.The business had revenue of $6.77 million during the quarter.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.